• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Fort Dodge inks deal with Banfield to conduct field trials

May 1, 2004

Portland, Ore.-Banfield, The Pet Hospital has reached an agreement with Fort Dodge Animal Health to conduct a clinical field trial on newly approved canine Duramune Adult vaccine with three-year duration of immunity data for distemper, hepatitis and parvovirus (DHP).

Portland, Ore.-Banfield, The Pet Hospital has reached an agreement with Fort Dodge Animal Health to conduct a clinical field trial on newly approved canine Duramune Adult vaccine with three-year duration of immunity data for distemper, hepatitis and parvovirus (DHP).

This post-approval study is in addition to the safety and efficacy challenge studies submitted to the USDA for regulatory approval.

Advertisement

Hugh Lewis, BVMS, MRCVS, DACVP, Banfield's senior vice president of practice development, explains, "We, like many practices, have taken the position that a change in re-vaccination strategy from one to every three years should be dictated by scientific evidence of proven efficacy, with challenge studies, and should involve extensive testing in the field." Lewis says Banfield has had much experience evaluating the safety and efficacy of other Fort Dodge canine vaccines, having given approximately 2 million doses in the past 12 months.

The clinical field trial will take place in two stages at Banfield hospitals across the United States, using standard vaccination procedures. The first stage of the study will include 1,000 adult dogs that are due for their annual vaccination booster, with all adverse observations recorded. Results will be reported to Banfield's Medical Standards Board and Fort Dodge Animal Health. The company intends to publish the results for review by the rest of the profession.

Banfield's computerized medical database will facilitate the compilation and analysis of the results. The second stage will be a post-marketing surveillance study of the 1,000 vaccinated dogs from the first stage of the study. This stage will track the overall health of the dogs, and possibly the level of protection afforded by the vaccine over the following three years.

Banfield Chief Medical Officer Will Novak, DVM, MBA ABVP, said that after positive results of stage one of the clinical field study are available, Banfield is planning to introduce the new vaccine as the standard vaccine in its preventive care schedule.


Advertisement

Latest News

To refer or to not refer

Advice panel for women interested in the veterinary field

AVMA president set to testify before Congress

New Hawaii-based pet CBD brand launches

View More Latest News
Advertisement